Skip to main content

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
Drug guidance

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy

Condition

Cancer

Blood and Immune System

17 February 2025

Published on 17 Feb 2025
Last Updated on 17 Feb 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended glofitamab for inclusion on the MOH List of Subsidised Drugs for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The decision was based on uncertain clinical effectiveness and unfavourable cost effectiveness of glofitamab compared with relevant comparators, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for glofitamab are provided in the Annex.

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy (17 Feb 2025) [PDF, 217 KB]

PES Glofitamab for previously treated relapsed or refractory diffuse large B-cell lymphoma (17 Feb 2025) [PDF, 97 KB]

Back to top